Dermatology

>

Latest News

FDA expands maralixibat label to include PFIC patients aged 12 months and older | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA expands maralixibat label to include PFIC patients aged 12 months and older

July 25th 2024

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

Roflumilast foam 0.3% sNDA submitted to treat scalp and body psoriasis in patients 12 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
Roflumilast foam 0.3% sNDA submitted to treat scalp and body psoriasis in patients 12 years and up

July 23rd 2024

FDA approves roflumilast cream 0.15% for atopic dermatitis in patients aged 6 years, older | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves roflumilast cream 0.15% for atopic dermatitis in patients aged 6 years and up

July 9th 2024

FDA approves ustekinumab-ttwe as biosimilar for pediatric plaque psoriasis, active psoriatic arthritis | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves ustekinumab-ttwe as biosimilar for pediatric plaque psoriasis, active psoriatic arthritis

July 9th 2024

Arcutis awaits FDA decision for roflumilast cream 0.15% to treat AD | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
Arcutis awaits FDA decision for roflumilast cream 0.15% to treat AD

July 9th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.